FDA Final Order: Metal-on-Metal Hip Implant Manufacturers Must File PMA
Manufacturers of two types of metal-on-metal (MoM) hip implants are now required to submit a PMA application. Today FDA issued the final rule for manufacturers of a hip joint metal/metal semi-constrained with a cemented acetabular component and the hip joint metal/metal semi-constrained with an uncemented acetabular component.
“FDA believes that there is insufficient evidence and information to conclude that general controls in combination with special controls would provide reasonable assurance of the safety and effectiveness of these devices,” according to FDA’s website. The devices will remain Class III. The agency has given manufacturers a deadline of May 18,2016 for which they must file PMA applications that include known or reasonably known risks, device effectiveness, and reports of all clinical and non-clinical investigations about device safety and effectiveness.
The agency also outlined its efforts to ensure the safety of MoM hip implants, which includes:
- Working with MoM hip implant manufacturers to evaluate devices in an MRI environment, along with developing labeling to enable safe scanning of patients with these implants
- Encouraging metal ion test labs to participate in a trace element proficiency testing program
- Continual review of published medical literature, MDRs, and post-approval study data from registries worldwide
- Launch of International Consortium of Orthopaedic Registries
- Establishment of Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee to discuss implant failure rates, metal ion testing, imaging methods, complications, patient risk, product labeling, and post-surgery considerations
Related Articles
-
Comply all the time, not just when FDA announces an inspection.
-
The FDA does not intend to enforce the GUDID submission requirements for Class I and unclassified devices, other than implantable, life-supporting or life-sustaining devices, regardless of whether they are consumer health products, before December 8, 2022.
-
Inspections are inevitable. If you receive 483s, follow these tips to quickly and adequately respond to the agency.
-
Significant changes made to the design or processing of finished medical devices, that are safe and effective in their intended use, require the review and subsequent approval of FDA. This includes changes in the indication for use.
About The Author
MedTech Intelligence Staff
The MedTech Intelligence staff consists of freelance journalists and industry contributing writers with decades of experience in covering medical device issues under the categories of business, market trends, product development, quality, regulatory, and operations.
You can contact our writing staff via our Contact Page.